Global Drug Forecast and Market Analysis to 2028
Key Learning Objectives
Learn how the HER2-Negative breast cancer market dynamics are expected to change between 2018 and 2028 across the 8 major markets (US, France, Germany, Italy, Spain, UK, Japan, and China)
Gain in-depth insight about the late-stage HER2-Negative breast cancer pipeline, including the products that are expected to dominate the market and the key drivers behind these.
Understand the unmet needs that key opinion leaders (KOLs) have identified in the HER2-Negative breast cancer treatment space and an analysis on whether the current pipeline will meet these needs.
Learn about some of the key R&D strategies, growth drivers, and barriers in the HER2-Negative breast cancer market across the 8MM.